Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
L04 IMMUNOSUPPRESSANTS
L04A IMMUNOSUPPRESSANTS
L04AF Janus-associated kinase (JAK) inhibitors
L04AF06 Peficitinib
D10721 Peficitinib hydrobromide (JAN/USAN) <JP>
Therapeutic category of drugs in Japan [BR:br08301]
3 Agents affecting metabolism
39 Other agents affecting metabolism
399 Miscellaneous
3999 Others
D10721 Peficitinib hydrobromide (JAN/USAN)
Drug groups [BR:br08330]
Anti-inflammatory
DG01985 Disease modifying anti-rheumatic drug (DMARD)
DG02020 JAK inhibitor
DG01853 Peficitinib
D10721 Peficitinib hydrobromide
Drug classes [BR:br08332]
Immunological agent
DG02020 JAK inhibitor
D10721 Peficitinib hydrobromide
Antirheumatic agent
DG01985 Disease modifying anti-rheumatic drug (DMARD)
D10721 Peficitinib hydrobromide
Target-based classification of drugs [BR:br08310]
Protein kinases
Non-receptor tyrosine kinases
JAK family
JAK1
D10721 Peficitinib hydrobromide (JAN/USAN) <JP>
JAK2
D10721 Peficitinib hydrobromide (JAN/USAN) <JP>
JAK3
D10721 Peficitinib hydrobromide (JAN/USAN) <JP>
New drug approvals in Japan [br08318.html]
Drugs with new active ingredients
D10721
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D10721
Drug groups [BR:br08330]
Anti-inflammatory
DG01985 Disease modifying anti-rheumatic drug (DMARD)
DG02020 JAK inhibitor
DG01853 Peficitinib